264 related articles for article (PubMed ID: 20152899)
1. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.
Kress HG; Boss H; Delvin T; Lahu G; Lophaven S; Marx M; Skorjanec S; Wagner T
Eur J Pharm Biopharm; 2010 Jun; 75(2):225-31. PubMed ID: 20152899
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications.
Sathyan G; Guo C; Sivakumar K; Gidwani S; Gupta S
Curr Med Res Opin; 2005 Dec; 21(12):1961-8. PubMed ID: 16368047
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
[TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
5. Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic reservoir and Durogesic D-Trans matrix transdermal fentanyl patches.
Van Nimmen NF; Veulemans HA
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 846(1-2):264-72. PubMed ID: 17030157
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
[TBL] [Abstract][Full Text] [Related]
8. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation.
Marier JF; Lor M; Morin J; Roux L; Di Marco M; Morelli G; Saedder EA
Br J Clin Pharmacol; 2007 Jan; 63(1):121-4. PubMed ID: 16939522
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects.
Marier JF; Lor M; Potvin D; Dimarco M; Morelli G; Saedder EA
J Clin Pharmacol; 2006 Jun; 46(6):642-53. PubMed ID: 16707411
[TBL] [Abstract][Full Text] [Related]
10. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
Solassol I; Caumette L; Bressolle F; Garcia F; Thézenas S; Astre C; Culine S; Coulouma R; Pinguet F
Oncol Rep; 2005 Oct; 14(4):1029-36. PubMed ID: 16142368
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
Hoy SM; Keating GM
Drugs; 2008; 68(12):1711-21. PubMed ID: 18681493
[TBL] [Abstract][Full Text] [Related]
12. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers.
Liu J; Zhou X
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):175-80. PubMed ID: 24424109
[TBL] [Abstract][Full Text] [Related]
14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers.
Lorch U; Pierscionek T; Freier A; Spencer CS; Täubel J
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):260-271. PubMed ID: 32748570
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.
Van Nimmen NF; Poels KL; Menten JJ; Godderis L; Veulemans HA
J Clin Pharmacol; 2010 Jun; 50(6):667-78. PubMed ID: 20097932
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
Freise KJ; Newbound GC; Tudan C; Clark TP
J Vet Pharmacol Ther; 2012 Aug; 35 Suppl 2():27-33. PubMed ID: 22731773
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.
Carroll GL; Hooper RN; Boothe DM; Hartsfield SM; Randoll LA
Am J Vet Res; 1999 Aug; 60(8):986-91. PubMed ID: 10451210
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
